capivasertib

{
  "id": "MLC-T-ONC-001391",
  "term": "capivasertib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with fulvestrant to treat adults with hormone-receptor positive, HER2-negative breast cancer that has spread and has an abnormal PIK3CA, AKT1, or PTEN gene. It is used in patients whose cancer came back or got worse during or after treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Capivasertib blocks a protein called AKT, which is involved in cell signaling, cell growth, and cell survival. Blocking this protein may help keep cancer cells from growing and may kill them. Capivasertib is a type of kinase inhibitor. Also called Truqap.",
    "A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers."
  ],
  "synonyms": [
    "Truqap"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/capivasertib/"
}